中国澳门启动首个新药临床试验

Core Viewpoint - The initiation of the clinical trial marks the completion of the "last piece of the puzzle" for the clinical research network in the Guangdong-Hong Kong-Macao Greater Bay Area [1] Group 1 - The first new drug clinical trial in Macau officially commenced on August 29 [1] - The trial is initiated by the multinational pharmaceutical company Boehringer Ingelheim and will be conducted at the Macau University of Science and Technology Clinical Trial Center [1] - This clinical trial is a double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of nerandomilast in patients with systemic autoimmune rheumatic disease-related interstitial lung disease [1]